Polymerase chain reaction

National Minority Quality Forum Announces Published Results of Baseline Minority and Rural Coronavirus Insights Study in Population Health Management

Retrieved on: 
Wednesday, December 20, 2023
Social Research (journal), Research, Population Health Management, Health, PCR, Social, COVID-19, CCSR, Coronavirus, Polymerase chain reaction, Biomarker, SVP, Minority, Vaccine

Study finds that despite past headlines, COVID-19 infection rates are higher amongst people of color.

Key Points: 
  • Washington, D.C.--(Newsfile Corp. - December 20, 2023) - The National Minority Quality Forum , a nonprofit research and advocacy organization dedicated to ensuring that minoritized populations receive optimal healthcare, Center for Clinical and Social Research (CCSR) shared that the Baseline Report for the Minority and Rural Coronavirus Insights Study (MRCIS) was published in Population Health Management.
  • MRCIS is a five-year longitudinal study on the effects of coronavirus with a particular focus on the impact of the virus in minority and rural communities.
  • Five Federally Qualified Health Centers (FQHCs) located in Florida, California, Illinois, Ohio and Louisiana were selected as participating sites.
  • The full paper can be viewed on the Population Health Management website here: https://www.liebertpub.com/doi/10.1089/pop.2023.0168 .

DNA Contamination of COVID Vaccines Explored in Journal of American Physicians and Surgeons

Retrieved on: 
Monday, December 11, 2023
Senate, AAPS, Plasmid, Pfizer, COVID-19 vaccine, Food, Physician, Cell nucleus, Messenger, Research, FDA, B cell, Myocarditis, DNA, PCR, COVID-19, Cancer, Polymerase chain reaction, Genome, Patient, Journal, Vaccine

“The plasmid DNA contamination theory is not a sensational internet rumor, but a reality-based hypothesis prompted by standard laboratory research performed by professional researchers,” she writes.

Key Points: 
  • “The plasmid DNA contamination theory is not a sensational internet rumor, but a reality-based hypothesis prompted by standard laboratory research performed by professional researchers,” she writes.
  • The Pfizer mRNA vaccine used in clinical trials employed a polymerase chain reaction (PCR) process to make the DNA that coded for the mRNA (Process 1).
  • But scaling up production to make millions of doses used plasmids, small circular pieces of DNA in bacterial cells (Process 2).
  • The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS) , a national organization representing physicians in all specialties since 1943.

Western Blotting Global Market Outlook to 2028, Featuring Leading Players Advansta, Bio-Rad Laboratories, Cell Signaling Technology, Li-Cor Biosciences, Merck, Perkinelmer and Thermo Fisher Scientific - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 28, 2023
Health, Other Health, Cell Signaling Technology, Protein, Agriculture, Antibody, Research, Prevalence, Lyme disease, ELISA, Disease, ESG, Thermo Fisher Scientific, PCR, Bio-Techne, HIV, Merck, Polymerase chain reaction, Growth, Bio-Rad Laboratories, Diagnosis, Environment

Increasing cases of HIV and Lyme disease are contributing to the demand for Western blotting.

Key Points: 
  • Increasing cases of HIV and Lyme disease are contributing to the demand for Western blotting.
  • Thus, Western blotting is being used increasingly to effectively differentiate between HIV and other antibodies and provide precise results.
  • Therefore, experts are increasingly recommending this test, and this is expected to drive market growth over the forecast period.
  • The report also covers market projections for 2028 and the market share for key market players.

Global Core Clinical Molecular Diagnostics Market Research Report 2023: Infectious Disease and Blood Screening, Genetic Testing, Cancer Screening Insights and Forecasts 2019-2029 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 21, 2023
Infectious Diseases, Biotechnology, Health, Medical Devices, Infection, Prevalence, Conditional sentence, Statistics, PCR, Cancer, USD, COVID-19, Genetic testing, Polymerase chain reaction, Research report, Vaccine

The "Global Core Clinical Molecular Diagnostics Market (2023 Edition): Analysis By Technology, By Application (Infectious Disease and Blood Screening, Genetic Testing, Cancer Screening, Others), By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Core Clinical Molecular Diagnostics Market (2023 Edition): Analysis By Technology, By Application (Infectious Disease and Blood Screening, Genetic Testing, Cancer Screening, Others), By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Core Clinical Molecular Diagnostics Market is expected to generate USD 11.04 billion by the end of 2029, up from USD 4.9 Billion in 2022.
  • During the forecast period, 2024-2029, the Global Core Clinical Molecular Diagnostics market is expected to grow at a CAGR of 10.7%.
  • As a result, this particular segment has emerged as one of the most prominent segments within the core clinical molecular diagnostics market.

Enzymatic DNA Synthesis Market to Surge to US$2.11 Billion by 2028 Driven by Advances in Synthetic Biology and Genetic Engineering Technologies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 20, 2023
Biotechnology, Genetics, Health, Proteomics, Custom, Research, Prevalence, CRISPR, DNA, Cas9, PCR, DSM-IV codes, Polymerase chain reaction, Synthetic biology, Genomics, Growth, Investment, Enzyme, Genetic engineering, Application, Fine chemical

The latest industry analysis on the global enzymatic DNA synthesis market projects a robust growth trend as the sector witnesses high demand fueled by breakthroughs in synthetic biology, genetic engineering, and therapeutic applications.

Key Points: 
  • The latest industry analysis on the global enzymatic DNA synthesis market projects a robust growth trend as the sector witnesses high demand fueled by breakthroughs in synthetic biology, genetic engineering, and therapeutic applications.
  • The research provides a detailed segmentation of the market, offering insightful data on various product types, technologies, applications, and end-users.
  • The application of enzymatic DNA synthesis in synthetic biology dominates the market, propelled by innovative developments in the fabrication of synthetic genes and organisms.
  • CRISPR-Cas9 integration – The incorporation of CRISPR-Cas9 in enzymatic DNA synthesis heralds a new era of precision in genetic manipulation, augmenting market expansion.

Global HIV Diagnostics and Therapeutics Markets Report 2023-2028 with Competitive Analysis of Medtronic, Abbott, Sanofi, Roche, Bio-Rad Laboratories, and Danaher - ResearchAndMarkets.com

Retrieved on: 
Monday, November 13, 2023
Infectious Diseases, Pharmaceutical, AIDS, Health, Polymerase chain reaction, FDC, Protease, STR, Therapy, HIV/AIDS, ART, Stephen Porter (professor), Social stigma, Viral load, WHO, Medtronic, Risk, EIA, Sanofi, Patient, PCR, NAT, Danaher Corporation, ELISA, CD4, HIV, Diagnosis, Roche, Growth, Pi, Medical device, Pharmaceutical industry, Vaccine, Marketing

The "Diagnostics and Therapeutics for HIV: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diagnostics and Therapeutics for HIV: Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The global market for diagnostics and therapeutics for HIV was valued at $28.8 billion in 2022.
  • The global HIV therapeutics market is poised for significant growth, with a focus on various drug classes.
  • It covers current regulations and guidelines for HIV diagnostics and therapeutics, presenting a survey of leading market players.

Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day

Retrieved on: 
Thursday, November 9, 2023
Esophageal cancer, AMP, Research, CLIA, National Cancer Institute, Esophageal disease, Case Western Reserve University, Lucid, CCNA1, Methylation, NGS, VIM, Polymerase chain reaction, Gene, Cancer, Invention, DNA, Vaccine

NEW YORK, Nov. 9, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that its CAP-accredited, CLIA-certified laboratory, LucidDx Labs, Inc., has launched the next generation of the EsoGuard® Esophageal DNA test ("EsoGuard 2.0") for the detection of esophageal precancer, having demonstrated enhanced assay performance and lower costs in extensive validation studies. All commercial and research samples received by the laboratory will now be processed using the EsoGuard 2.0 assay. Lucid also announced that it will be hosting an Investor Day on December 13, 2023, in New York City.

Key Points: 
  • Lucid also announced that it will be hosting an Investor Day on December 13, 2023, in New York City.
  • The EsoGuard assay involves first extracting DNA from esophageal cells collected by the EsoCheck® Cell Collection Device.
  • Lucid will host an Investor Day event to be held in New York, NY on December 13, 2023.
  • Details on how to register for the Investor Day will be made available on the Investor Relations section of the Company's website.

World Emerging Infectious Disease Diagnostics Market Research Report 2023: Respiratory Infections Take Center Stage in Infectious Disease Diagnostics Post-COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 25, 2023
Infectious Diseases, Health, Other Health, RSV, Region, Infection, Chlamydia, Respiratory syncytial virus, SARS-CoV-2, Government, Urinary tract infection, Influenza, CRISPR, Ebola, PCR, Developed country, Virus, Virulence, POCT, Whole genome sequencing, Growth, Point-of-care testing, STI, NGS, Streptococcus, RT-LAMP, COVID-19, Mumps, Hospital, Gonorrhea, WGS, Polymerase chain reaction, Bacteria, Rubella, Hepatitis, Syphilis, Tuberculosis, Diagnosis, Gastroenteritis, Zika fever, POC, Pharmaceutical industry, Vaccine, Medical imaging, Medical device

The emergence of the COVID-19 pandemic has had a profound and far-reaching impact on infectious disease diagnostics worldwide.

Key Points: 
  • The emergence of the COVID-19 pandemic has had a profound and far-reaching impact on infectious disease diagnostics worldwide.
  • North America, encompassing both the United States and Canada, currently holds the largest share in the global emerging infectious disease diagnostics market.
  • Some of the common bacterial infections include respiratory infections such as tuberculosis and streptococcal infections and sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis.
  • Hospitals and clinics play a critical role in the field of infectious disease diagnostics, serving as important centers for patient evaluation and testing.

Personalized Medicine Key to IVD Procedure Volumes' 10% Annual Growth

Retrieved on: 
Monday, October 23, 2023
Pregnancy, Patient, Insurance, Pharmacology, Sale, Ageing, Incidence, Steam, IVD, Health, Physician, Molina Healthcare, Genetics, HIV, Histology, PCR, Abbott Laboratories, Microbiology, Growth, Disease, NGS, Fungal infection, COVID-19, Medicine, Hospital, Chemistry, Polymerase chain reaction, Eye, HAI, Diagnosis, Medical device, Vaccine, Medical imaging, Pharmaceutical industry, Immunoassay, Hematology, WHO model list of essential in vitro diagnostics

ARLINGTON, Va., Oct. 23, 2023 /PRNewswire/ -- The in vitro diagnostic (IVD) industry is on track again after the disruptions of the pandemic. The overall volume of IVD procedures will rise steadily throughout most of the world, boosted by aging population trends, proliferating epidemiological patterns, increasing availability of healthcare funding, and widespread adoption of patient care strategies that emphasize early disease detection and preventive medicine. As a result of these key factors, the global volume of IVD procedures is forecast to increase almost 10% annually from 2023-2028, according to the diagnostic market research report In Vitro Diagnostic (IVD) Procedure Volumes (Chemistry, Immunoassays, Hematology, Microbiology, Histology, Point of Care), 2023-2028.

Key Points: 
  • Beyond this, one of the most intriguing trends to watch is personalized medicine, which is also known as precision medicine.
  • IVD is an integral part of personalized medicine as it provides critical information needed to make treatment decisions.
  • Specific examples where IVD devices provide personalized medicine include blood glucose tests, pregnancy tests, cancer screening and in-home HIV testing.
  • Many of the IVD tests are benefiting from the uptake of personalized medicine which is expected to continue to increase.

Global and Regional Acute Care Syndromic Testing Market Analysis Report 2023: Respiratory Diseases and Bacterial Panels Dominate Acute Care Syndromic Testing Market in 2022 - Forecasts to 2032 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 16, 2023
Managed Care, Infectious Diseases, Health, Diagnosis, Disease, Incidence, Infection, Partnership, Data science, Bacteria, Target, Prescription, Treatment, Prevalence, PCR, Irritable bowel syndrome, Polymerase chain reaction, Mergers and acquisitions, Pandemic, Laboratory, Patient, FDA, Key, Abbott Laboratories, Growth, Region, Hospital, Microscopy, Physician, Pharmaceutical industry, Vaccine, Epidemic

The "Acute Care Syndromic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Target, Sample Type, End User and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute Care Syndromic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Target, Sample Type, End User and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The acute care syndromic testing market has the potential to provide advanced healthcare solutions, with a focus on early detection and management of infectious diseases.
  • Respiratory Diseases Dominance: Respiratory panels hold the largest market share (56.29%) in 2022, ideal for distinguishing between viral and bacterial respiratory pathogens.
  • Hospitals as Key Users: Hospitals are the primary end users (42.53%) of syndromic testing, particularly in North America and Europe.